Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?
Jan 14, 2022
auto_awesome
Experts Jacob Laubach and Peter Voorhees discuss the impact of Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma. They highlight findings from the GRIFFIN and CASSIOPEIA trials, showing enhanced response rates, minimal residual disease negativity, and improved progression-free survival. The podcast explores the benefits of incorporating Daratumumab into treatment regimens and its role in enhancing overall outcomes for multiple myeloma patients.
DEROTUMAMAB maintenance post-transplant improves depth of response and progression free survival.
Incorporating DEROTUMAMAB into therapy components leads to better outcomes and enhanced response rates.
Deep dives
Results of Griffin trial after 24 months of maintenance therapy
The Griffin trial was a randomized phase two clinical trial for transplant eligible patients with newly diagnosed multiple myeloma. Patients received either standard RVD induction therapy or RVD plus DEROTUMAM. Key findings after 24 months of maintenance therapy showed that the stringent complete response rate improved with DEROTUMAM maintenance. MRT negativity rates also increased with longer maintenance therapy periods, demonstrating 64% MRT negativity with DEROTUMAM and LENELITIMIDE after two years.
Significance of DEROTUMAMAB in improving depth of response
Incorporation of DEROTUMAMAB into induction and post-transplant consolidation therapy led to improved depth of response. Data from the Cassiopeia trial in Europe similarly showed better depth of response and improved progression free survival with DEROTUMAMAB. The ongoing use of DEROTUMAMAB in maintenance therapy post-consolidation continues to enhance response rates and may improve progression free survival.
Comparison and ongoing studies
Comparing the Griffin and Cassiopeia trials revealed the importance of incorporating DEROTUMAMAB into therapy components for better outcomes. Ongoing studies like the GMMG trial with isotuximab and the SWAG 1803 trial with DEROTUMAMAB maintenance after transplant aim to clarify the impact of maintenance therapy on progression free survival, especially for patients who received DEROTUMAMAB in frontline treatment.
During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach, Dana-Farber Cancer Institute, Boston, US, and Peter Voorhees, Levine Cancer Institute, Charlotte, US. We asked, Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM): What have we learned from GRIFFIN and CASSIOPEIA trials?
In this podcast, Laubach and Voorhees discuss the findings from the randomized phase II GRIFFIN trial (NCT02874742) and the CASSIOPEIA trial (NCT02541383).